Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lichtiger

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Clinical Gastroenterology|December 1, 1986
Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel diseaseD B Sachar, H Smith, S Chan, et al.
The New England Journal of Medicine|June 30, 1994
Cyclosporine in severe ulcerative colitis refractory to steroid therapyS Lichtiger, D H Present, A Kornbluth, et al.
Alimentary Pharmacology & Therapeutics|October 20, 2010
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapyS Lichtiger, D G Binion, D C Wolf, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Clinical Gastroenterology|December 1, 1986
Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel diseaseD B Sachar, H Smith, S Chan, et al.
The New England Journal of Medicine|June 30, 1994
Cyclosporine in severe ulcerative colitis refractory to steroid therapyS Lichtiger, D H Present, A Kornbluth, et al.
Alimentary Pharmacology & Therapeutics|October 20, 2010
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapyS Lichtiger, D G Binion, D C Wolf, et al.
Pageof 2